



\$450 Million
Common Stock
Financing

LEERINK PARTNERS
Lead-Left Bookrunner
September 2023

Leerink Partners Serves as Lead-Left Bookrunner for Immunovant's (Nasdaq: IMVT) \$450 Million Common Stock Financing

Key Transaction Highlights

- Launched on September 26th post-close and priced September 27th post-close
- The offering followed the September 26th release of positive initial IMVT-1402 phase 1 SAD and 300 mg subcutaneous MAD data which led to a one-day stock price reaction of 97.0%.
- Well oversubscribed from both new and existing investors
- Base deal upsized from \$300 million to \$450 million.
- Consisted of 7,370,000 shares of common stock in the public offering and 4,473,684 shares of common stock in the concurrent private placement shares at a price of \$38.00 per share, representing a 3.8% discount to last sale
- Immunovant intends to use the net proceeds from the offering, together with its existing cash, to fund the acceleration of IMVT-1402 development, working capital and other general corporate purposes.
- This is Leerink Partners' 4th equity offering for Immunovant and 42nd equity offering in 2023.

About Immunovant

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases.

If you would like to unsubscribe from this distribution, click [here](#).

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF LEERINK PARTNERS LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

BOSTON
53 State Street
40th Floor
Boston, MA 02109

CHARLOTTE
2151 Hawkins Street
Suite 1025
Charlotte, NC 28203

NASHVILLE
40 Burton Hills Boulevard
Suite 200
Nashville, TN 37215

NEW YORK
1301 Avenue of the Americas
12th Floor
New York, NY 10019

SAN FRANCISCO
255 California Street
12th Floor
San Francisco, CA 94111